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C ontrolling hepatitis B virus (HBV) activation after orthotopic liver transplantation (OLT) has 
been acknowledged to be easier than before,  as the 
administration of a nucleos(t)ide analogue in combina-
tion with hepatitis B immunoglobulin (HBIG) is a 
promising protocol [1, 2].  However,  because HBIG is a 
product of human donated blood,  it carries a risk of 
being infected with unknown pathogens.  In addition,  
HBIG is extremely expensive,  costing approximately 
$600 USD every 3 months in Japan [3].  Newer-
generation nucleos(t)ide analogues such as entecavir or 
tenofovir have a very strong HBV-DNA reduction 
power with few adverse effects (AEs),  but the life-long 
administration of these drugs is also expensive and car-
ries the risk of unknown occult AEs,  as these agents are 
nucleos(t)ide analogues that bind DNA.  Therefore,  the 
active immunization of recipients with an HBV vaccine 
is a candidate approach to reducing the required 
amounts of HBIG and nucleos(t)ide analogue for treat-
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Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide ana-
logue and hepatitis B immunoglobulin (HBIG) combination,  but the high cost and the potential risk of 
unknown infection associated with HBIG remain unresolved issues.  Low-cost recombinant hepatitis B virus 
(HBV) vaccine administration is a potential solution to these problems.  We retrospectively analyzed the rate 
and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B),  n = 28 
patients; acute liver failure-type B (ALF-B),  n = 8; and non-HBV-related end-stage liver disease (non-B ESLD) 
who received a liver from anti-hepatitis B core antibody-positive donors,  n = 13.  A positive anti-hepatitis B sur-
face antibody response was achieved in 29% (8/28) of the LC-B group,  88% (7/8) of the ALF-B group,  and 44% 
(4/9) of the adult non-B ESLD group.  All four non-B ESLD infants showed vaccine success.  The predictive fac-
tors for a good response in LC-B were young age,  marital donor,  and high donor age.  ALF-B and non-B ESLD 
infants are thus good vaccination candidates.  LC-B patients with marital donors are also good candidates,  per-
haps because the donated liver maintains an efficient immune memory to HBV,  as the donors had already been 
infected in adulthood and showed adequate anti-HBV immune responses.
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ment [4].  Vaccines containing hepatitis B surface anti-
gen (HBsAg) are widely administered to healthcare 
workers and students,  with an estimated efficacy of 
≥ 90%,  and they are considered reasonably safe [5].
Several research groups have investigated the vac-
cine response in post-OLT patients with liver cirrhosis 
type B (LC-B) and acute liver failure type B (ALF-B).  
The vaccine effects were not sufficient for LC-B,  
whereas some success was noted for ALF-B.  Even a 
double-dose vaccine trial resulted in only 2 of 24 
patient (8.3%) responders among those receiving 
deceased-donor OLT (DDLT) [6].  A prospective study 
with mainly LC-B patients in DDLT revealed success in 
9 of 27 patients (33%) [7],  with the lymphocyte-to-eo-
sinophil ratio being the only marker predicting vaccine 
responders.
Most of the relevant studies have been conducted in 
post-DDLT patients,  and the details of the donors have 
not been analyzed.  In Japan,  the brain-dead donor pool 
is very small,  and living donor liver transplantation 
(LDLT) is widely performed [8].  This situation should 
be improved,  as LDLT carries substantial risks to the 
living donors.  In this environment,  the health of the 
donors can also be investigated.
Evidence regarding the effects of HBV vaccine on 
post-LDLT patients is lacking.  We reported that 9 of 22 
(41%) post-OLT LC-B patients responded well to vac-
cines [9].  To identify good candidates for vaccine 
administration,  we herein report a summary of our 
substantial experience with patients,  including those 
with non-HBV-related end-stage liver disease (non-B 
ESLD) who received a liver from an anti-hepatitis B core 
antibody (HBcAb)-positive donor,  with a focus on the 
HBV vaccine effects.
Patients and Methods
Study design and patients. We conducted a ret-
rospective analysis of the medical records of 49 post-
OLT patients who received an HBV vaccination.  These 
49 patients were 28 with LC-B,  8 with ALF-B,  and 13 
with other non-B ESLD,  including 4 infants with non-B 
ESLD.  The patients were diagnosed and treated at 
Okayama University Hospital between August 1998 and 
May 2017.
This study design was approved by the Ethics 
Committee of Okayama University Graduate School of 
Medicine,  Dentistry and Pharmaceutical Sciences and 
Okayama University Hospital (No. Rin1192),  and it 
adhered to the Declaration of Helsinki.  All patients 
provided their written informed consent for their cases 
to be used in the present retrospective analyses.
Treatment protocol. OLT was performed at the 
Department of Gastroenterological Surgery Transplant 
and Surgical Oncology,  Okayama University Hospital.  
The HBV vaccination was started ≥ 1 year after the OLT 
in each patient’s case.  The vaccine consisted of recom-
binant purified HBsAg (Bimmugen®; Kaketsuken,  
Kumamoto,  Japan; or Heptavax®-II; MSD,  Tokyo).  A 
10-μg pro dose was injected subcutaneously twice at 
4-week intervals,  and then once after 10-12 weeks.  The 
patients who showed anti-HBsAb titers > 100 mIU/mL 
without HBIG for a minimum of 6 months were defined 
as good responders.
Clinical assessments and statistical analyses. All 
clinical assessments performed in this study involved 
the collection of the patients’ medical history and labo-
ratory examination findings.  Every datum presented in 
these analyses is the median value with the range.  A 
univariate analysis was performed to examine the cor-
relation between the HBV vaccine response and the 
clinical characteristics of the patients with different liver 
disease backgrounds (LC-B,  ALF-B,  and non-B ESLD).  
We performed a multivariate logistic regression analysis 
to examine the correlation between the HBV vaccine 
response and the clinical parameters in LC-B.  In the 
univariate and multivariate analyses,  a p-value < 0.05 
was defined as significant.  All statistical analyses were 
performed using the JMP® software program,  ver. 13 
(SAS,  Cary,  NC,  USA).
Results
Patient backgrounds. The demographic and 
other baseline characteristics for all of the patients as 
well as the donor-related factors are summarized in 
Table 1.  Some of the missing data and DDLT related 
donor data were not obtained.  The parameters of these 
data are specified.  The HBV vaccination started at 55 
(range 49-59) years of age in the LC-B group,  40 (33-
55) years in the ALF-B group,  51 (21-71) years in the 
adult non-B ESLD group,  and 4 (1-8) years in the infant 
non-B ESLD group.  The numbers (percentages) of 
HBsAg-positive patients at OLT were 28 (100%) in the 
LC-B group,  2 (33%) in the ALF-B group,  0 (0%) in the 
adult non-B ESLD group,  and 0 (0%) in the infant 
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non-B ESLD group.
The numbers (percentages) of hepatitis B surface 
antibody (HBsAb)-positive patients at OLT were 2 
(7.1%) in the LC-B group,  4 (67%) in the ALF-B group,  
1 (11%) in the adult non-B ESLD group,  and 0 (0%) in 
the infant non-B ESLD group.  The positive rate of HBV 
DNA copies in LC-B was 30%.  HCC was detected at the 
OLT in 15 patients (54%) in the LC-B group and 2 
patients (22%) in the adult non-B ESLD group.
Regarding the donor-related factors,  OLT was per-
formed at the median donor age (range) of 45 (30-49) 
years in the LC-B group,  36 (29-48) years in the ALF-B 
group,  41 (32-65) years in the adult non-B ESLD group,  
and 60 (58-64) years in the infant non-B ESLD group.  
A blood relationship (percentage) between donors and 
recipients was found in 17 pairs (61%) of the LC-B 
group,  8 pairs (100%) in the ALF-B group,  5 pairs 
(56%) in the adult non-B ESLD group,  and 4 pairs 
(100%) in the infant non-B ESLD group.  The numbers 
(percentages) of donors with high levels of anti-HBsAb 
(> 100 mIU/mL) were 10 (38%) in the LC-B group,  1 
(14%) in the ALF-B group,  4 (50%) in the adult non-B 
ESLD group,  and 4 (100%) in the infant non-B ESLD 
group.
Response rate in vaccination. Good vaccine 
responses were achieved in 8 patients (29%) with LC-B,  
7 patients (88%) with ALF-B,  4 patients (44%) with 
non-B ESLD (adults),  and all 4 patients (100%) with 
non-B ESLD (infants) (Fig. 1).  The overall success rate 
was 42% (19/45) in the adults and 100% (4/4) in the 
infants.
HBV vaccination for LC-B. The correlation 
between the HBV vaccine response and the clinical 
characteristics of the LC-B patients is shown in Table 2.  
A good vaccine response in blood-relation donors was 
noted in only 1 of 17 cases (5.9%),  although a good 
vaccine response was noted in unrelated donors in 7 of 
11 cases (64%) (p = 0.0007).  Regarding blood relation-
ships (or lack thereof),  a non-consanguineous marital 
relationship (7 of 9 cases,  78%) was significantly associ-
ated with vaccine success compared with sibling (1 of 5 
cases,  20%),  offspring (0 of 10 cases,  0%),  and paren-
tal relationships (0 of 2 cases,  0%) as well as DDLT (0 of 
2 cases,  0%) (p = 0.0008).
Older female donors were also associated with a 
good response.  ABO blood type compatibility between 
donors and recipients (6 of 12 cases,  50%) was associ-
ated with a good response compared to identical blood 
types between donors and recipients (2 of 16 cases,  
13%) (p = 0.028).  In addition,  anti-hepatitis B e anti-
body (HBeAb)-positive donors and anti-HBsAb- 
positive recipients at OLT were significantly correlated 
with a good response.  The multivariate analysis showed 
that donor non-relation (mostly marital donors),  a 
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????? ? Demographic and other baseline characteristics of recipient- and donor-related factors
LC-B ALF-B non-B ESLD (adult) non-B ESLD (infant)
N 28  8  9  4
Recipient-related factors
Age at OLT 52 (44-56) 36 (28-53) 47 (20-65)  1 (1-6)
Age at start of vaccine 55 (49-59) 40 (33-55) 51 (21-71)  4 (1-8)
Sex (M) 25 (89%)  2 (25%)  3 (33%)  4 (100%)
HBsAg positive at OLT 28 (100%) 2/6 (33%)  0 (0%)  0 (0%)
HBsAb positive at OLT  2 (7.1%) 4/6 (67%)  1 (11%)  0 (0%)
HBV DNA at OLT (≥3.7 log IU/mL) 8/27 (30%)  0 (0%)  0 (0%) Not done
MELD at OLT 15 (10-18) 23 (16-38) 19 (15-25) Not done
HCC at OLT 15 (54%)  0 (0%)  2 (22%)  0 (0%)
Donor-related factors
Age at OLT 45 (30-49) 36 (29-48) 41 (32-65) 60 (58-64)
Sex (M) 12 (43%)  5 (63%)  5 (56%)  2 (50%)
ABO (identical) 16 (57%)  7 (88%)  6 (67%)  4 (100%)
Blood relation (yes) 17 (61%)  8 (100%)  5 (56%)  4 (100%)
Donor HBsAb (>100 mIU/mL) 10/26 (38%) 1/7 (14%) 4/8 (50%)  4 (100%)
Donor HBcAb (＋) 12/26 (46%) 2/6 (33%) 8/8 (100%)  4 (100%)
ALF-B,  acute liver failure type B; HBcAb,  anti-hepatitis B core antibody; HBsAb,  anti-hepatitis B surface antibody; HBsAg,  hepatitis B 
surface antigen; HBV,  hepatitis B virus; HCC,  hepatocellular carcinoma; LC-B,  liver cirrhosis type B; MELD,  Model for End-Stage Liver 
Disease criteria; non-B ESLD,  non-HBV-related end stage liver diseases; OLT,  orthotopic liver transplantation.
higher donor age,  and a younger recipient age at vac-
cine start were significant factors influencing a good 
response.
HBV vaccination for ALF-B. The HBV vaccina-
tion for ALF-B was successful (88%),  as previously 
reported [9].  No marked differences in patient back-
ground were observed between the HBV vaccine 
responders and non-responders,  as most achieved suc-
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????? ? The correlation between HBV vaccine response and clinical characteristics in LC-B
(A) Recipient-related factors
Vaccine success 
 number (%)
Univariate  
analysis, p-value
Multivariate  
analysis,  p-value
Age at OLT ≥52 3/15 (20) 0.280
<52 5/13 (38)
Age at start of vaccine ≥55 3/14 (21) 0.401 0.0166＊＊
<55 5/14 (36)
Sex M 7/25 (28) 0.849
F 1/3 (33)
HBsAg at OLT ＋ 8/28 (29) －
－ 0/0
HBsAb at OLT ＋ 2/2 (100) 0.020＊ 0.090
－ 6/26 (23)
HBcAb at OLT ＋ 8/28 (29) －
－ 0/0
HBeAg at OLT ＋ 5/11 (45) 0.114
－ 3/17 (18)
HBeAb at OLT ＋ 4/16 (25) 0.630
－ 4/12 (33)
HBV-DNA at OLT (>3.7 log IU/mL) ＋ 3/8 (38) 0.566
－ 5/19 (26)
MELD at OLT ≥15 5/16 (31) 0.824
<15 3/11 (27)
HCC ＋ 5/15 (33) 0.547
－ 3/13 (23)
NA ＋ 8/27 (30) 0.407
－ 0/1 (0)
INR ≥1.58 5/14 (36) 0.401
<1.58 3/14 (21)
A B C D
29%
71%
12%
56%
88%
44% 100%
???? ? The good responder rate for HBV vaccination in post-OLT recipients.  HBV vaccination succeeded in 8 (29%) of 28 patients with 
HBV-related cirrhosis (LC-B,A),  7 (88%) of 8 patients with acute HBV liver failure (ALF-B,B),  4 (44%) of 9 patients with adult non-HBV-
related end-stage liver diseases (adult non-B ESLD,C),  and all 4 patients (100%) with infant non-B ESLD (infant non-B ESLD,D).  Dark-
gray ﬁlled areas indicate success and light-gray ﬁlled areas indicate failure of HBV vaccination.
cess (Table 3).
HBV vaccination for adult non-B ESLD. The 
vaccine response was not sufficiently good in our adult 
non-B ESLD patients,  although we expected a good 
response.  The vaccine responders in the adult non-B 
ESLD group showed a severe pre-OLT condition,  indi-
cated by higher Model for End-Stage Liver Disease cri-
teria (MELD) scores as shown in Table 4.  One of the 
possible vaccine success-related factors found in the 
LC-B analysis,  donor non-relation,  tended to result in 
a good response compared to donor relation (75% vs.  
20%) (p = 0.090).
HBV vaccination for infant non-B ESLD. The 
HBV vaccination was completely successful in the 
infant non-B ESLD group,  although the number of 
patients in this group was small (n = 4).
Discussion
Post-OLT HBV vaccinations were administered to 
LC-B,  ALF-B,  and non-B ESLD patients with HBV-
infected donor livers.  The good responder rate was 
highest in the infants with non-B ESLD,  high in ALF-B,  
and low in the LC-B group and the adults with non-B 
ESLD.  The good responders in the LC-B group con-
sisted mainly of young patients,  as expected,  whereas 
liver transplantation from older donors and marital 
donors showed unexpectedly significant immune 
induction.
OLT is usually the only curative therapeutic option 
for patients with acute and chronic liver failure [10],  
HCC [11],  or primarily genetic metabolic defects of the 
liver [12].  LC-B and ALF-B have been major indica-
tions for OLT.  The use of nucleos(t)ide analogues in 
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(B) Donor-related factors
Vaccine success 
number (%)
Univariate 
analysis,  p-value
Multivariate  
analysis,  p-value
Age at OLT† ≥45 7/13 (54) 0.008＊ 0.0016＊＊
<45 1/13 (7.7)
Sex M 1/12 (8.3) 0.034＊ 0.090
F 7/16 (44)
ABO compatible 6/12 (50) 0.028＊ 0.050
identical 2/16 (13)
incompatible 0/0
Blood relation related 1/17 (5.9) 0.0007＊ 0.0009＊＊
unrelated 7/11 (64)
Relation spouse 7/9 (78) 0.0008＊
brother 1/5 (20)
oﬀspring 0/10 (0)
parent 0/2 (0)
brain-dead patient 0/2 (0)
HBsAb ＋ 5/11 (45) 0.165
－ 3/15 (20)
HBsAb ≥100 5/10 (50) 0.095
<100 3/16 (19)
HBcAb ＋ 5/12 (42) 0.264
－ 3/14 (21)
HBeAb ＋ 4/5 (80) 0.010＊ 0.080
－ 4/21 (19)
HBcAb,  anti-hepatitis B core antibody; HBeAb,  anti-hepatitis B e antibody; HBeAg,  hepatitis B e antigen; HBsAb,  anti-hepatitis B sur-
face antibody; HBsAg,  hepatitis B surface antigen; HBV,  hepatitis B virus; HCC,  hepatocellular carcinoma; INR,  international normal-
ized ratio for prothrombin time; LC-B,  liver cirrhosis type B; MELD,  Model for End-Stage Liver Disease criteria; NA,  nucleoside/nucleo-
tide analogs; OLT,  orthotopic liver transplantation.  
＊p-value for statistical signiﬁcance is deﬁned as p<0.05 in univariate analysis.  ＊＊p-value for statistical signiﬁcance is deﬁned as p<0.05 
in multivariate analysis.  †Because the 26 OLT includes 2 cases of deceased donor OLT,  the ages of the donors cannot be determined in 
the 2 cases.
combination with HBIG has been accepted as the best 
way to control the recurrence of HBV DNA [4].  
However,  given that HBIG is made from donated 
human blood,  it is very expensive to procure and car-
ries a risk of harboring unknown infectants or patho-
gens.  Historically,  many HBIG reduction protocols 
have been introduced with some degree of success [4].  
Strong and safe new nucleos(t)ide analogues such as 
entecavir or tenofovir alafenamide,  have recently been 
used as a monotherapy [13].  However,  remaining 
HBsAg-free with an anti-HBs-positive status is still 
deemed important.  Active immunization with recom-
binant HBsAg is a promising approach for achieving an 
anti-HBs response at low-cost using safe methods.
We conducted a recombinant HBsAg vaccination 
protocol for post-OLT patients to prevent the reactiva-
tion of HBV.  The HBV vaccination succeeded in 8 
patients (29%) with LC-B,  7 (88%) with ALF-B,  and 4 
(44%) with adult non-B ESLD.  Although the success 
rate in the LC-B group was not as high in the present 
study as in previous reports,  we identified several fac-
tors that predict a good response.  A non-blood rela-
tionship between the donor and recipient—observed 
mainly in transplants between married partners—was a 
significant predictive factor of a good response,  as the 2 
patients with DDLT showed no response.
Our previous investigation in a relatively small 
number of patients (22 LC-B patients and 5 ALF-B 
patients) revealed that higher donor age,  marital trans-
plant,  and high-titer anti-HBsAb in the donor were 
predictive of a good response to HBV vaccination [9].  
We observed a good response with marital donors and 
older donors in the present study as well.  The marital 
status means that the donors were infected with HBV in 
adulthood,  and an immune tolerance could not be 
achieved; therefore,  a strong immune response had 
been established after marriage.  Although we did not 
include the anti-HBsAb titer in the present multivariate 
analysis,  the univariate analysis indicated that a higher 
anti-HBsAb titer was correlated with vaccine success.  
Marital donors usually have an immune response 
against the HBV of the recipient that should be polar-
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????? ? The correlation between HBV vaccine response and clinical characteristics in ALF-B
(A) Recipient-related factors
Vaccine success number (%) Univariate analysis, p-value
Age at OLT ≥36 4/5 (80) 0.312
<36 3/3 (100)
Age at vaccine start ≥40 3/4 (75) 0.216
<40 4/4 (100)
Sex M 2/2 (100) 0.431
F 5/6 (83)
HBsAg at OLT ＋ 1/2 (50) 0.105
－ 4/4 (100)
HBsAb at OLT ＋ 4/4 (100) 0.105
－ 1/2 (50)
HBcAb at OLT ＋ 5/6 (83) －
－ 0/0
HBeAg at OLT ＋ 0/0 －
－ 5/6 (83)
HBeAb at OLT ＋ 5/6 (83) －
－ 0/0
HBV-DNA at OLT (>3.7 log IU/mL) ＋ 0/0 －
－ 7/8 (88)
MELD at OLT ≥23 4/4 (100) 0.216
<23 3/4 (75)
HCC ＋ 0/0 －
－ 7/8 (88)
NA ＋ 4/5 (80) 0.312
－ 3/3 (100)
INR ≥2.05 5/5 (100) 0.137
<2.05 2/3 (67)
ized to the same sequence.
In one previous study,  HBV vaccination in LDLT 
donors was reported to have the capacity to transfer an 
anti-HBV immune response to the recipient [14].  Of 
note,  however,  the adoptive transfer of the HBV-
specific immune response was established in recipients 
only when the anti-HBsAb titers were very high.  Our 
present analyses demonstrated that high anti-HBsAb 
was a predictive factor only in the univariate analysis.  
This might be because of the relatively small number of 
patients.
Since almost all of the present post-OLT ALF-B 
patients responded well to the vaccine,  we were unable 
to determine any vaccine response-predictive factors.  
Such a high response rate to HBV vaccination was also 
shown previously [9].  It is widely accepted that ALF-B 
patients already have a very strong HBV-specific 
immune response causing fatally severe inflammation.
Contrary to our expectations,  the success rate in the 
post-OLT adult non-B ESLD patients was not very high 
in the present study.  Although the recipient immune 
system failed to tolerate HBV and was believed to easily 
induce an anti-HBsAb response,  the frequency of a 
vaccine response among the recipients was low.  This 
phenomenon is a new finding that should be kept in 
mind for the management of patients who have under-
gone OLT,  as a vaccination can be expected to be inef-
fective in some patients.  We found that a high pre-OLT 
MELD score was related to vaccination success in this 
group.  The MELD score is calculated based on the 
serum bilirubin level,  the international normalized 
ratio for prothrombin time (INR),  and the serum creat-
inine level.  A high MELD score was reported to be 
positively correlated with the serum interleukin (IL)-21 
level in HBV-related acute-on-chronic liver failure [15].  
IL-21 has been shown to accelerate the HBsAg clearance 
and promote anti-HBsAb production [16].  Such phe-
nomena might suggest that a high MELD score reflects 
a good immune response against HBV vaccine; how-
ever,  our post-OLT patients would not have been expe-
riencing a cytokine storm,  and the number of patients 
in this group may have been too small to draw definitive 
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(B) Donor-related factors
Vaccine success number (%) Univariate analysis,  p-value
Age at OLT ≥36 3/4 (75) 0.216
<36 4/4 (100)
Sex M 5/5 (100) 0.137
F 2/3 (67)
ABO compatible 1/1 (100) 0.592
identical 6/7 (86)
incompatible 0/0
Blood relation related 7/8 (88) －
unrelated 0/0
Relation spouse 0/0 0.465
brother 3/4 (75)
oﬀspring 2/2 (100)
parent 2/2 (100)
brain-dead patient 0/0
HBsAb ＋ 2/2 (100) 0.390
－ 4/5 (80)
HBsAb ≥100 1/1 (100) 0.563
<100 5/6 (83)
HBcAb ＋ 2/2 (100) －
－ 4/4 (100)
HBeAb ＋ 1/1 (100) －
－ 5/5 (100)
ALF-B,  acute liver failure type B; HBcAb,  anti-hepatitis B core antibody; HBeAb,  anti-hepatitis B e antibody; HBeAg,  hepatitis B e anti-
gen; HBsAb,  anti-hepatitis B surface antibody; HBsAg,  hepatitis B surface antigen; HBV,  hepatitis B virus; HCC,  hepatocellular carci-
noma; INR,  international normalized ratio for prothrombin time; MELD,  Model for End-Stage Liver Disease criteria; NA,  nucleoside/
nucleotide analogs; OLT,  orthotopic liver transplantation.
mechanistic conclusions.
Soejima et al.  [17] reported that HBV vaccination 
was successful in 6 of 11 patients (55%) who underwent 
an LDLT for ALF-B (3 patients) and non-B ESLD 
(8 patients).  Their findings differed from ours in that 
the average age of the 6 responders was significantly 
younger than that of the non-responders.  One reason 
for this discrepancy may be that their participants 
included 3 non-adults,  as our infants responded very 
well.  Although the number of patients was relatively 
small,  we should pay attention to the low vaccine 
response in the present adult non-B ESLD group,  as it is 
likely that patients in this group are not good candidates 
for post-OLT HBV vaccination.
We noted that all 4 pediatric cases of non-B ESLD 
successfully achieved anti-HBV immunity after HBV 
vaccination.  Similar observations of a high frequency of 
immune induction in infants have been described by 
other investigators: 17 of 19 patients (89%) [18],  33 of 
37 patients (89%) [19],  41 of 49 patients (84%) [20],  47 
of 60 patients (78%) [21],  and 36 of 67 patients (54%) 
[22].  In the present study,  however,  among adult OLT 
patients who did not have ALF-B,  there was no signifi-
cant difference in the age of recipients at OLT.  The 
immune response induced by an HBV vaccine has been 
shown to be higher in newborns than in adults because 
of the higher antibody and memory Th2 responses with 
lower primary IFN-γ responses in newborns [23].  
These findings may explain the success rate discrepancy 
between the infants and adults in the present study.
Pathophysiologically,  memory B lymphocytes spe-
cific for HBsAg seem to play an important role in the 
induction of anti-HBV immunity.  HBsAg-specific 
memory B lymphocytes were detected in HBs-
vaccinated subjects and continuously produced anti-
HBsAb [24].  In contrast,  the induction of HBsAg-
specific regulatory T cells was demonstrated in OLT 
patients with HBV-related liver disease immunized by 
an HBV vaccine,  resulting in a poor response of OLT 
recipients to conventional vaccines [25].  Differences in 
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????? ? The correlation between HBV vaccine response and clinical characteristics in adult non-B ESLD
(A) Recipient-related factors
Vaccine success number (%) Univariate analysis, p-value
Age at OLT ≥47 2/5 (40) 0.764
<47 2/4 (50)
Age at vaccine start ≥51 2/5 (40) 0.764
<51 2/4 (50)
Sex M 2/3 (67) 0.340
F 2/6 (33)
HBsAg at OLT ＋ 0/0 －
－ 4/9 (44)
HBsAb at OLT ＋ 1/1 (100) 0.182
－ 3/8 (38)
HBcAb at OLT ＋ 0/0 －
－ 4/9 (44)
HBeAg at OLT ＋ 0/0 －
－ 4/9 (44)
HBeAb at OLT ＋ 0/0 －
－ 4/9 (44)
HBV-DNA at OLT (>3.7 log IU/mL) ＋ 0/0 －
－ 2/5 (40)
MELD at OLT ≥19 4/6 (67) 0.0297＊
<19 0/3 (0)
HCC ＋ 0/2 (0) 0.094
－ 4/7 (57)
NA ＋ 0/0 －
－ 4/9 (44)
INR ≥1.65 3/5 (60) 0.286
<1.65 1/4 (25)
the balance between memory B cells and regulatory T 
cells may determine the outcome of HBV vaccination.
Toward the goal of boosting the immunization 
effects,  double-dose immunization,  elongation of vac-
cine protocols,  and adjuvant usage have been tested.  A 
Japanese study showed that a double-dose vaccine 
resulted in 18 of 40 HBV-related liver disease patients 
(45%) responding to an HBV vaccine [22].  A relatively 
large number of vaccinations was shown to result in the 
induction of HBV immunity: 19 times (range 11.5-30 
times) in LC-B and 4 times (range 2.5-5 times) in 
ALF-B before ceasing HBIG treatment [9].  The use of 
several adjuvant vaccines has also been reported,  
although the efficacy of this approach was not very high 
at 44% [26, 27].  Careful monitoring should be contin-
ued after vaccine success,  as even when immunization 
with HBV has been achieved,  the gradual loss of anti-
HBsAb (− 46% at 1 year,  − 57% at 2 years,  and − 82% at 
≥ 3 years) has been reported to occur in post-OLT 
patients despite high levels of anti-HBsAb prior to OLT 
[28].
In conclusion,  a prophylactic HBV vaccination for 
OLT patients succeeded in 29% of LC-B patients,  88% 
of ALF-B patients,  44% of adult non-B ESLD patients,  
and 100% of infant non-B ESLD patients.  The predic-
tive factors for a good response in LC-B were marital 
transplant,  higher donor age,  and younger age at the 
vaccine start.  The present adult non-B ESLD patients 
were not good responders,  whereas infant non-B ESLD 
patients appear to be good responders who should 
receive an HBV vaccination because of the strong 
immune response against HBV.  In order to take advan-
tage of the HBV vaccine in OLT for HBV-related liver 
diseases,  further investigations into the use of HBV 
vaccines should be performed,  including evaluations of 
the nature and dose of the vaccine itself,  the timing,  
interval,  and frequency of administration,  and the use 
of adjuvants and combinations with other therapeutic 
modalities.
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(B) Donor-related factors
Vaccine success number (%) Univariate analysis, p-value
Age at OLT ≥41 3/5 (60) 0.286
<41 1/4 (25)
Sex M 2/5 (40) 0.764
F 2/4 (50)
ABO compatible 0/1 (0) 0.094
identical 2/6 (33)
incompatible 2/2 (100)
Blood relation related 1/5 (20) 0.090
unrelated 3/4 (75)
Relation spouse 3/4 (75) 0.165
brother 1/2 (50)
oﬀspring 0/2 (0)
parent 0/1 (0)
brain-dead patient 0/0
HBsAb ＋ 3/7 (43) 0.216
－ 1/1 (100)
HBsAb ≥100 1/4 (25) 0.148
<100 3/4 (75)
HBcAb ＋ 4/8 (50) －
－ 0/0
HBeAb ＋ 1/4 (25) 0.148
－ 3/4 (75)
HBcAb,  anti-hepatitis B core antibody; HBeAb,  anti-hepatitis B e antibody; HBeAg,  hepatitis B e antigen; HBsAb,  anti-hepatitis B sur-
face antibody; HBsAg,  hepatitis B surface antigen; HBV,  hepatitis B virus; HCC,  hepatocellular carcinoma; INR,  international normal-
ized ratio for prothrombin time; MELD,  Model for End-Stage Liver Disease criteria; NA,  nucleoside/nucleotide analogs; non-B ESLD,  
non-HBV-related end stage liver diseases; OLT,  orthotopic liver transplantation.   
＊p-value for statistical signiﬁcance is deﬁned as p<0.05 in univariate analysis.
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